Amarin Corp Plc (AMRN)

[HDGabor]

It's already included. It's not in the 'INDICATIONS AND USAGE' section, however you could find it as 'WARNINGS AND PRECAUTIONS':

Lovaza:
- LOVAZA may increase levels of LDL. Monitor LDL levels periodically during therapy. (5.1)
- There is a possible association between LOVAZA and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. (5.3)

Epanova:
- In some patients, EPANOVA increases LDL-C levels. LDL-C levels should be monitored periodically during therapy with EPANOVA. (5.1)

Omtryg:
- OMTRYG may increase levels of LDL. Monitor LDL levels periodically during therapy. (5.1)
- There is a possible association between omega-3-acid ethyl esters and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. (5.3)

All of them (and Vascepa also) contain in the same section:
- In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
- Use with caution in patients with known hypersensitivity to fish and/or shellfish.